HealthPolitics

STAT+: Who will get the first psychedelic approved?

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 03/11/2026, 15:51:24 UTC.

Briefings

A biotech competition for the first psychedelic approval is intensifying as non-profit Compass Pathways closes in on Pfizer, Neurocrine, and Alkermes. The article notes that major pharmaceutical companies like Pfizer, Neurocrine, and Alkermes reported earnings on Monday night, highlighting the high stakes of the race. The text explicitly states that the full story is available via a link, but the provided evidence does not contain specific dates, numbers, or names of other competitors beyond the named companies.

Key points

• Compass Pathways is identified as a frontrunner in the race to secure the first psychedelic drug approval.
• Non-profit organization Compass Pathways is closing in on the approval race alongside major pharmaceutical companies.

Context

The article discusses the biotech landscape during the midterms, noting that major companies like Pfizer, Neurocrine, and Alkermes reported earnings on Monday night. The full story regarding the competition is available through a link provided in the source text.

Limitations

The provided evidence is limited to the article's headline, publication date, and a brief mention of major companies reporting earnings. Specific dates, numbers, or names of other competitors in the race are not included in the source text.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 03/11/2026, 16:23:57 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeicqybfildrpqilexaroosn3j3d3npd46if53cda46nhvgbouxji2i